Literature DB >> 10616579

Fibrinolytic treatment of intraventricular haemorrhage preceding surgical repair of ruptured aneurysms and arteriovenous malformations.

L Mayfrank1, V Rohde, J M Gilsbach.   

Abstract

Previous studies have indicated that intraventricular administration of tissue-type plasminogen activator (TPA) might improve the prognosis of patients with intraventricular haemorrhage (IVH). In aneurysmal IVH, fibrinolytic treatment was always preceded by surgical repair of the aneurysm, since the risk of recurrent haemorrhage from a non-occluded aneurysm was estimated to be high. We reviewed a series of patients with IVH secondary to ruptured aneurysms (n = 4) or arteriovenous malformation (AVM; n = 1) who underwent emergency intraventricular administration of TPA before repair of the bleeding source. Fibrinolysis resulted in rapid decrease of haematoma volume and of ventricular dilatation, and prevented ventricular catheters from becoming obstructed. No intracranial haemorrhages or other complications occurred. The results suggest that the presence of recently ruptured aneurysms or AVM is not necessarily a contraindication for intraventricular administration of TPA. The potentially life saving benefits might outweigh the inherent risks of recurrent haemorrhage in carefully selected patients with massive IVH, in whom ventricular distension, periventricular brain compression, obstruction of CSF flow, and elevated ICP appear to be major determinants for the outcome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10616579     DOI: 10.1080/02688699943862

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  6 in total

Review 1.  Intraventricular fibrinolysis for intracerebral hemorrhage with severe ventricular involvement.

Authors:  Dimitre Staykov; Juergen Bardutzky; Hagen B Huttner; Stefan Schwab
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

2.  Intraventricular hemorrhage secondary to intranidal aneurysm rupture-successful management by arteriovenous malformation embolization followed by intraventricular tissue plasminogen activator: case report.

Authors:  Glen A Pollock; Ali Shaibani; Issam Awad; H Hunt Batjer; Bernard R Bendok
Journal:  Neurosurgery       Date:  2011-02       Impact factor: 4.654

3.  Pharmacokinetics and Pharmacodynamics of Tissue Plasminogen Activator Administered Through an External Ventricular Drain.

Authors:  Andreas H Kramer; Craig Jenne; Jessalyn K Holodinsky; Stephanie Todd; Derek J Roberts; Paul Kubes; David A Zygun; Michael D Hill; Caroline Leger; John H Wong
Journal:  Neurocrit Care       Date:  2015-12       Impact factor: 3.210

Review 4.  A review of stereotaxy and lysis for intracranial hemorrhage.

Authors:  Uzma Samadani; Veit Rohde
Journal:  Neurosurg Rev       Date:  2008-10-01       Impact factor: 3.042

5.  Intraventricular thrombolysis after endovascular treatment of a ruptured arteriovenous malformation.

Authors:  Arthur Wang; Abhishek Ray; Yin C Hu
Journal:  BMJ Case Rep       Date:  2016-05-24

6.  Massive intraventricular haemorrhage from aneurysmal rupture: patient proportions and eligibility for intraventricular fibrinolysis.

Authors:  Dennis J Nieuwkamp; Bon H Verweij; Gabriël J E Rinkel
Journal:  J Neurol       Date:  2009-10-13       Impact factor: 4.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.